hepsulfam has been researched along with Thrombopenia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geller, RB; Grochow, LB; Janisch, L; Larson, RA; Milton, J; Ratain, MJ | 1 |
| Hillyer, CD; Kim, BK; McClure, HM; Myers, LA; Orkin, JL; Saral, R; Srinivasiah, J; Strobert, EA; Swenson, RB; Winton, EF | 1 |
| Cheung, E; Hanson, SR; Harker, LA; Kelly, AB; Marzec, UM; Nichol, JL; Stead, RB; Tomer, A | 1 |
| Donehower, RC; Ettinger, DS; Forastiere, AA; Grochow, LB; Hendricks, CB; Lubejko, B; McGuire, WP; Rowinsky, EK; Sartorius, S | 1 |
| Brown, TD; Havlin, KA; Koeller, JM; Kuhn, JG; Marshall, MV; Ravdin, PM; Rodriguez, G; Von Hoff, DD | 1 |
3 trial(s) available for hepsulfam and Thrombopenia
| Article | Year |
|---|---|
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Blast Crisis; Brain Diseases; Coma; Dose-Response Relationship, Drug; Electroencephalography; Female; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukopenia; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sulfonic Acids; Thrombocytopenia | 1995 |
Phase I and pharmacokinetic study of hepsulfam (NSC 329680).
Topics: Adult; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukopenia; Male; Metabolic Clearance Rate; Neoplasms; Neutropenia; Sulfonic Acids; Thrombocytopenia | 1991 |
A phase I clinical and pharmacokinetic trial of hepsulfam.
Topics: Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Sulfonic Acids; Thrombocytopenia | 1991 |
2 other study(ies) available for hepsulfam and Thrombopenia
| Article | Year |
|---|---|
Effect of recombinant human interleukin-6 (rhIL-6) and rhIL-3 on hematopoietic regeneration as demonstrated in a nonhuman primate chemotherapy model.
Topics: Animals; Bone Marrow; Female; Hematopoiesis; Hematopoietic Stem Cells; Hemoglobins; Interleukin-3; Interleukin-6; Macaca mulatta; Male; Neutropenia; Recombinant Proteins; Reticulocytes; Sulfonic Acids; Thrombocytopenia | 1994 |
Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
Topics: Alkylating Agents; Animals; Bone Marrow; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Macaca mulatta; Male; Megakaryocytes; Neoplasm Proteins; Neutropenia; Neutrophils; Platelet Count; Polyethylene Glycols; Proto-Oncogene Proteins; Receptors, Cytokine; Receptors, Thrombopoietin; Recombinant Proteins; Sulfonic Acids; Thrombocytopenia; Thrombopoietin; Time Factors | 1997 |